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Abstract. Epstein-Barr virus-associated gastric carci-
noma (EBVaGC) is a distinct subtype of gastric cancer 
characterized by clinicopathological features including 
lymphoepithelioma-like histology. Aberrant expression of 
activation-induced cytidine deaminase (AID) as a genomic 
modulator was demonstrated through pathogen-related nuclear 
factor κB (NF-κB) signaling in Helicobacter pylori-associated 
gastric cancer. To elucidate whether or not AID expression is 
relevant to carcinogenesis in EBVaGC, immunohistochemical 
expression of AID and AID-regulatory factors between 
EBVaGC and EBV-non-associated gastric carcinoma (GC) 
were evaluated, each using 15 cases of GC with lymphoid 
stroma (GCLS) and other types of GC. Aberrant expression 
of AID, NF-κB and paired box 5 (PAX5) were significantly 
decreased in EBVaGC (0/11, 1/11 and 1/11) compared with 
in EBV-non-associated GC (7/19, 12/19 and 11/19) (P=0.025, 
0.005 and 0.01, respectively); however, no significant differ-
ence in c-Myb proto-oncogene expression was identified. 
AID expression was also decreased in EBV-associated GCLS 
(0/10) compared with in EBV-non-associated GCLS (3/5). 
Unexpectedly, decreased expression of NF-κB and PAX5 
was observed in GCLS (1/15 and 2/15) compared with in GC 
without LS (12/15 and 10/15) (P<0.001 and P=0.003, respec-
tively). Decreased AID expression observed in EBVaGC is 
consistent with the reported molecular characterization of 
hypermethylation and rare somatic gene mutation in EBVaGC. 
Only PAX5 was identified to be significantly associated with 
venous invasion (P=0.022). The results of the present study 
suggest that pathogen-induced AID expression may be irrel-
evant to carcinogenesis of EBVaGC, whereas it contributes to 
carcinogenesis in certain types of EBV-non-associated GC.
Introduction
Epstein-Barr virus (EBV), also known as human herpes virus 
4, is one of the most common human viruses. The majority of 
individuals are infected during infancy or childhood, such that 
the majority of adults have been infected and have established 
lifelong latent infections (1). EBV was the first human onco-
virus to be described, which was identified from a Burkitt's 
lymphoma cell line in 1964 (2). Subsequent studies revealed 
that EBV caused infectious mononucleosis and many different 
human malignancies including nasopharyngeal carcinoma, 
Hodgkin's lymphoma, extranodal natural killer/T-cell 
lymphoma, lymphoproliferative disorders in immunocompro-
mised hosts and a number of types of gastric cancer (1).
EBV-associated gastric carcinoma (EBVaGC or EBV(+) 
GC) is a distinct subtype of gastric cancer that accounts 
for <10% of GC (gastric carcinoma). EBVaGC is defined 
by the monoclonal proliferation of carcinoma cells with 
latent EBV infection, as demonstrated using EBV-encoded 
small RNA (EBER) in situ hybridization (1). EBVaGC has 
characteristic clinicopathological features including a lympho-
epithelioma-like histology and favorable prognosis (3). It has 
been histologically subdivided into two types: A lymphoepi-
thelioma-like carcinoma (LELC) type and conventional type 
adenocarcinoma. The LELC type is also referred to as ‘GC 
with lymphoid stroma (GCLS)’. In total, >80% of GCLS cases 
have been identified to exhibit EBV(+) tumors (3,4).
A previous study highlighted the important role 
of activation-induced cytidine deaminase (AID), a 
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nucleotide-editing enzyme that is essential for the somatic 
hypermutation and class-switch recombination of the 
immunoglobulin gene, as a genomic modulator in inflam-
mation-associated cancer development in digestive organs 
including Helicobacter pylori-associated gastric cancer, 
hepatitis C virus-positive hepatocellular carcinoma and 
colitis‑associated colon cancers (5). Consistent with the finding 
that a number of transcription factors, including nuclear 
factor-κB (NF-κB), mediate the expression of AID in B cells, 
the proinflammatory cytokine stimulation of numerous types 
of gastrointestinal epithelial cells, including gastric, colonic, 
hepatic and biliary epithelia, induced aberrant AID expres-
sion through the NF-κB signaling pathway (6). NF-κB is a 
key molecule in inflammation‑associated carcinogenesis, and 
NF-κB activation in epithelial cells and malignant cells is 
involved in generating genomic instability through aberrant 
AID expression, cell growth, proliferation, survival, angiogen-
esis and epithelial-mesenchymal transition (7).
The expression and activity of AID are tightly regulated 
at the levels of transcription, post-transcription and enzymatic 
function. Four distinct DNA regions (regions I to IV) of the 
AID gene locus contain binding sites for multiple transcrip-
tion factors. Region I functions as a promoter containing 
the binding site for NF-κB, a transcriptional activator. In B 
and non-B cells, enhancer elements in region II bind to the 
activators paired box 5 (PAX5) and transcription factor E2A, 
whereas silencer elements in region II bind to the repressor 
proteins c-Myb proto-oncogene (c-Myb) and transcription 
factor E2F in order to counter the activities of transcriptional 
activators (8).
Honjo et al (9) described pathogen-induced AID expres-
sion in gastric cancer (caused by H. pylori), adult T cell 
leukemia/lymphoma (caused by human T lymphotrophic 
virus 1), hepatoma (caused by hepatitis C virus) and Burkitt's 
lymphoma (caused by EBV), but not in classical Hodgkin's 
lymphoma (caused by EBV) (9). However, to the best of 
our knowledge, aberrant AID expression in EBVaGC has 
not yet been elucidated. The majority of EBVaGCs exhibit 
marked lymphoid stroma surrounding cancer cells, which 
suggests pathogen-induced chronic inflammation. Chronic 
inflammation, regardless of the infectious agent involved, 
serves important roles in the development of various types 
of cancer, particularly in digestive organs (5). Therefore, 
the aim of the present study was to determine whether the 
inflammation‑associated cancer development theory through 
aberrant AID expression via a pathogen-related NF-κB signal 
also applies to EBVaGC and GCLS.
In order to elucidate the question of whether or not 
EBV-induced AID expression is a causative factor of carci-
nogenesis in EBVaGC, the aberrant expression of AID 
and AID-regulatory factors including NF-κB (activator), 
PAX5 (activator) and c-Myb (repressor) were immunohisto-
chemically evaluated and compared between EBVaGC and 
EBV-non-associated GC, and also between GCLS and GC 
without LS.
Materials and methods
Tumor samples. Formalin‑fixed paraffin‑embedded (FFPE) 
tumor samples were obtained from 30 patients who had 
undergone surgical resection at Tottori University Hospital 
between January 2005 and December 2014, and who were 
histopathologically diagnosed with GCLS (n=15; 14 males 
and 1 female) or age-sex-stage-matched other gastric cancers 
(GC without LS) (n=15; 14 males and 1 female). The mean 
age ± standard deviation (SD) was 64.7±9.4 years (range, 
45‑77 years). The tumor location was defined as the upper 
third, middle third and lower third of the tissue or remnant. All 
samples were histopathologically classified according to the 
Japanese Classification of Gastric Carcinoma (10). The present 
study was approved by the Institutional Ethics Committee of 
Tottori University (Yonago, Japan; no. 2483).
Evaluation of surrounding mucosal inflammation. The 
grading of gastritis in the non-cancerous mucosa adjacent to 
a tumor was evaluated and scored according to the updated 
Sydney System (USS) including H. pylori infection (11). 
Gimenez staining was used to detect H. pylori.
Immunohistochemical staining of AID, NF‑κB, c‑Myb, 
PAX5 and latent membrane protein 1 (LMP‑1). Immuno- 
histochemical staining was performed using the following 
primary antibodies: Anti-AID (#39-2500; dilution, 1:200; 
Invitrogen; Thermo Fisher Scientific, Inc., Waltham, MA, 
USA), NF-κB (#ab86299, polyclonal; dilution, 1:100; 
Abcam, Cambridge, MA, USA), PAX5 (#M7307; dilu-
tion, 1:30; Dako; Agilent Technologies, Inc., Santa Clara, 
CA, USA), c-Myb (#LS-C49755; dilution, 1:150; LifeSpan 
BioSciences, Inc., Seattle, WA, USA) and LMP-1 (#M0897; 
dilution, 1:100; Dako; Agilent Technologies, Inc.). Sections 
were cut to a thickness of 4 µm, deparaffinized in xylene 
and dehydrated in descending dilutions of ethanol. Antigen 
retrieval was performed using a pressure cooker at 120˚C 
with citrate buffer (pH 6.0) for 10 min (AID and c-Myb) 
or with Target Retrieval Solution (pH 9.0; Dako; Agilent 
Technologies, Inc.) for 20 min (NF-κB, PAX5 and LMP-1). 
Endogenous peroxidase activity was blocked by a 5-min 
incubation at room temperature with 3% hydrogen peroxi-
dase. Sections were incubated with primary antibodies and 
antibody diluents with background-reducing components 
(Dako; Agilent Technologies, Inc.) at room temperature for 
120 min (AID, NF-κB and PAX5) or at 4˚C overnight (c‑Myb 
and LMP-1). Horseradish peroxidase (HRP) -conjugated 
goat anti-mouse IgG (EnVision™+/HRP; #K4000; predi-
luted; AID, NF-κB, PAX5 and LMP-1) or goat anti-rabbit 
IgG (EnVision™+/HRP; #K4002; prediluted, c-Myb) was 
applied as the secondary antibody (both from Dako; Agilent 
Technologies, Inc.). Sections were incubated with secondary 
antibody at room temperature for 30 min prior to washing in 
PBS. Diaminobenzidine was used as the chromogen. Sections 
were counterstained with Mayer's hematoxylin and eosin.
Immunostaining densities were assessed by pathologists 
using the ECLIPSE 80i light microscope and NIS Elements D 
3.2 imaging software (both from Nikon Corporation, Tokyo, 
Japan) and the H-score method, as described previously (12): 
H-score = (% tumor cells unstained x 0) + (% tumor cells weakly 
stained x 1) + (% tumor cells moderately stained x 2) + (% 
tumor cells strongly stained x 3). H-scores ranged between 0 
(100% negative tumor cells) and 300 (100% strongly positive 
tumor cells).
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For AID, lymphocytes from germinal centers in lymphoid 
follicles were used as internal positive controls because they 
were primarily activated B cells and were strongly stained 
throughout the specimens. H-scores were calculated for AID, 
NF-κB, PAX5 and c-Myb for each sample. The following 
threshold values were adopted: 105 for AID, 125 for NF-κB, 
70 for PAX5 and 100 for c-Myb.
In situ hybridization (ISH) of EBER1. ISH was performed 
using a fluorescein isothiocyanate-labeled probe comple-
mentary to an EBER1 sequence as described previously (13). 
Sections of FFPE tissue (thickness, 4 µm) were used for ISH 
and were imaged using a light microscope.
Statistical analysis. Statistical analyses were performed 
using Fisher's exact test, χ2 test, Mann-Whitney U test and 
Kaplan-Meier survival estimates using SPSS software (version 
23.0.0.0; IBM SPSS, Armonk, NY, USA). P<0.05 was consid-
ered to indicate a statistically significant difference.
Results
Clinicopathological findings. Representative histology, 
ISH and immunostaining images of EBV(+) GCLS, EBV(-) 
GC without LS and EBV(-) GCLS are presented in Fig. 1. 
Clinicopathological data are presented in Tables I-III.
Detection of EBV markers in tissue samples suspected of 
EBVaGC. The expression of EBER1 was only detected in 
10/15 GCLS samples, the majority of which were histopatho-
logically suspected of EBVaGC. On the other hand, 1/15 GC 
without LS samples tested positive for EBER1. All 30 samples 
were negative for LMP-1 (data not shown).
Grading of atrophic gastritis in sample tissue backgrounds. 
Background atrophic gastritis was evaluated and scored in 
sample tissues according to the USS. The mean USS scores 
(± SD) in EBV (+)GC (n=11) and in EBV (-)GC (n=19) were 
1.67 (±0.57) and 1.88 (±0.38), respectively, and were not 
significantly different (P=0.328).
EBV(‑) GC is more likely to express AID and AID‑regulatory 
factors. AID H‑scores of ≥105 were considered to be positive. 
Similarly, NF-κB, PAX5 and c‑Myb H‑scores of ≥125, ≥70 and 
≥100, respectively, were considered to be positive.
The positive H-score rates of AID and its regulatory 
factors were compared between EBV(+) GC (n=11) and EBV(-) 
GC (n=19). The rates were 0/11 vs. 7/19 (0 vs. 37%; P=0.025) 
for AID, 1/11 vs. 12/19 (9 vs. 63%; P=0.005) for NF-κB, 
1/11 vs. 11/19 (9 vs. 58%; P=0.01) for PAX5 and 5/11 vs. 6/19 
(45 vs. 32%; P=0.35) for c-Myb for EBV(+) GC and EBV(-) 
GC, respectively. The positive rates of AID, NF-κB and PAX5, 
but not c-Myb, were significantly increased in EBV(-) GC 
compared with in EBV(+) GC (Table III).
No association between the expression of AID and USS 
scores was identified (P=0.623; Table II).
Certain cases of EBV(‑) GCLS express AID and PAX5 (AID 
activator). H-scores of AID and its regulatory factors were 
compared between EBV(+) GCLS (n=10) and EBV(-) GCLS 
(n=5). The positive H-score rate of AID and PAX5 was 
increased in EBV(-) GCLS (3/5, 60% for AID and 2/5, 40% 
for PAX5) compared with in EBV(+) GCLS (both 0/10, 0%). 
However, no significant differences were identified for AID 
or AID-regulatory factors between EBV(+) GCLS and EBV(-) 
GCLS, owing to an insufficient number of cases examined 
(Table III).
Expression of NF‑κB and PAX5 is decreased in GCLS 
compared with in GC without LS. The aberrant expression of 
NF-κB and PAX5 was significantly decreased in GCLS [1/15 
(7%) and 2/15 (13%); P<0.001] compared with in GC without 
LS [12/15 (80%) and 10/15 (67%); P=0.003] (Table III).
AID and AID‑regulatory factors except PAX5 are not associ‑
ated with clinicopathological parameters. The relationships 
of the expression of AID and its regulatory factors with 
clinicopathological parameters including tumor category, 
lymphatic invasion, venous invasion, node category, stage, 
location of GC, age and USS were investigated. No association 
between AID and its regulatory factors except PAX5 and the 
clinical parameters examined in EBV(+) and EBV(-) GCs was 
identified (n=30), whereas PAX5 expression was significantly 
associated with venous invasion (P=0.022; Table II).
Association between AID and AID‑regulatory factors and 
survival rates. Among 30 patients who participated in the 
present study, only one succumbed to GC (Table I, case 13). 
Therefore, in the survival analysis, it was not possible to 
conclude whether AID and AID-regulatory factors affected 
the survival rate.
Discussion
Previous comprehensive genome analyses using next-gener-
ation sequencing of various cancer tissues have revealed 
that cancer cells have numerous nucleotide alterations (14). 
Cancer cells are considered to be generated from the step-
wise accumulation of genetic alterations in various genes in 
inflammation‑associated carcinogenesis (7). AID, a nucleo-
tide-editing enzyme that is essential for somatic hypermutation 
and class-switch recombination of the immunoglobulin gene, 
is also known to serve a role as a genomic mutator in carci-
nogenesis (9). Shimizu et al (7) demonstrated that pathogenic 
bacterial or viral factors and subsequent inflammatory reac-
tions in H. pylori-related gastritis, chronic viral hepatitis, 
Barrett's esophagus and inflammatory bowel disease lead to 
the aberrant expression of AID in various epithelial cells via 
NF-κB activation, which causes the accumulation of genetic 
alterations in tumor-related genes. The aberrant expression 
of AID was observed in the gastric epithelium and gastric 
cancer cells with an H. pylori-infected background (10,15,16). 
EBVaGC, a distinct type of GC, the majority of cases of 
which have lymphoid stroma, is an EBV‑infected and inflam-
mation-associated cancer. The results of the present study 
identified that the aberrant expression of AID and NF-κB 
was significantly decreased in EBVaGC compared with in 
EBV-non-associated GC, and also that EBV was not likely to 
be involved in pathogen-induced AID expression via NF-κB 
activation in gastric cancers. These results suggested that the 
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genomic modulation of tumor-related genes by EBV-induced 
AID expression is not a primary causative mechanism in 
the carcinogenesis of EBVaGC. Unexpectedly, the aberrant 
expression of NF-κB was less frequent in EBVaGC with LS or 
GCLS compared with in GC without LS. A potential reason 
for the decreased expression of NF-κB is that EBV-LMP-1, 
a strong activator of NF-κB, was not expressed in EBVaGC 
with latency type I or II EBV infection. However, this does not 
explain the decreased expression of NF-κB in GCLS compared 
with in GC without LS regardless of EBV infection because 
LS is a hallmark of chronic inflammation. Furthermore, no 
significant differences were identified in the expression of 
AID between GCLS and GC without LS. These results suggest 
that LS, a histological characteristic of chronic inflammation, 
does not necessarily reflect NF‑κB-inducing conditions, and 
that NF-κB and homeobox protein C4 may promote the tran-
scription of AID (8). The activation of NF-κB is a complex 
process induced by various stimuli, including microbial and 
viral products, cytokines, DNA damage, oxidative damage and 
radiation (17). Aberrant NF-κB activity has been demonstrated 
to contribute to a number of human diseases that possess an 
immune or inflammatory component, including tumorigenesis 
and H. pylori infection (17). Other stimuli, including H. pylori 
infection, appear to be more important in the induction of aber-
rant AID expression via NF-κB in the stomach compared with 
EBV infection (15). In the present study, no significant differ-
ences were observed in mean USS scores or H. pylori‑infected 
rates between EBVaGC and EBV-non-associated GC. No asso-
ciation was identified between EBV infection and H. pylori 
infection in gastric cancer patients from northern Brazil (18). 
Furthermore, no association between the expression of AID 
and USS scores was identified; however, H. pylori infection is 
generally considered to induce atrophic gastritis and intestinal 
metaplasia with the aberrant expression of AID, which subse-
quently leads to gastric cancers through the accumulation of 
genetic mutations (19).
PAX5, known as a B cell‑specific activator protein, serves 
a role as an activator for AID (9). In the present study, the 
aberrant expression of PAX5 and AID was more frequently 
observed in EBV-non-associated GC compared with in 
EBVaGC (P=0.01 and P=0.025, respectively). The expression 
of PAX5 was also increased in GC without LS compared with 
in GCLS (P=0.003). This was attributed to the aberrant expres-
sion of PAX5 contributing to the induction of AID expression 
in EBV-non-associated GC, the majority of cases of which 
exhibited no LS background. PAX5 has been identified as a 
tumor suppressor gene and the epigenetic inactivation of PAX5 
through the direct up-regulation of p53 is associated with a 
poor prognosis in gastric cancer patients (20). However, it is 
noteworthy that PAX5 expression was significantly associated 
with venous invasion of GC in that study.
The cellular oncogene c-Myb, a v-Myb avian myelo-
blastosis viral oncogene homolog, has been implicated in 
leukemogenesis, and c-Myb was demonstrated to be increased 
in acute myeloid leukemia and acute lymphoblastic leukemia 
samples (21). c-Myb also serves a role as a repressor or silencer 
of the expression of AID (8). The aberrant expression of c-Myb 
in the present study was not significantly different between 
EBVaGC and EBV-non-associated GC, or between GCLS and 
GC without LS. The expression of c-Myb as a silencer for the 
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induction of AID appears to serve certain roles in the expres-
sion of AID in gastric cancers, regardless of the EBV status.
The Cancer Genome Atlas Research Network recently 
provided a comprehensive molecular characterization of 
gastric adenocarcinoma and defined EBVaGC as a specific 
subtype, which displays recurrent mutations in phos-
phoinositide 3-kinase catalytic α polypeptide (PIK3CA) and 
AT-rich-interaction domain 1A (ARID1A), extreme DNA 
hypermethylation, and the amplification of genes encoding 
c-Jun-associated kinase 2, cluster of differentiation 274 (also 
known as programmed death ligand 1) and programmed cell 
death 1 ligand 2 (also known as programmed death ligand 2) 
with the extremely rare tumor protein 53 gene mutation (22). 
Furthermore, mutations in PIK3CA and ARID1A may precede 
EBV infection because mutation events have been detected in 
chronically inflamed and H. pylori-infected gastric mucosa (23). 
EBVaGC is characterized by extreme DNA hypermethylation 
and relatively rare somatic gene mutations. The decreased aber-
rant expression of AID observed in EBVaGCs in the present 
study is consistent with the relatively small number of somatic 
gene mutations detected using the comprehensive molecular 
analysis in this specific subtype of GC.
The prognostic effects of EBV positivity on gastric cancer 
are controversial (23). However, a recent meta-analysis of 4599 
GC cases identified a decreased mortality rate in EBVaGC 
following adjustment for the cancer stage and other factors (24). 
The 10‑year disease‑specific rate of patients with EBVaGCLS 
(89.1%) was previously demonstrated to be significantly 
Table II. Association between expression of AID and AID-regulatory factors and clinicopathological parameters in gastric 
cancers (n=30) regardless of EBV infection.
   NF-κB (+)   PAX-5 (+)   c-Myb (+)
Factor AID (+) P-value (AID activator) P-value (AID activator) P-value (AID silencer) P-value
T  0.572  0.215  0.831  0.465
  1b (n=18) 3  10  7  7
  2 (n=6) 2  2  3  1
  3 (n=6) 2  1  2  3
ly  0.539  0.100  0.134  0.218
  0 (n=5) 1  0  0  3
  1 (n=17) 3  9  8  4
  2 (n=8) 3  4  4  4
v  0.456  0.317  0.022a  0.292
  0 (n=10) 3  3  1  3
  1 (n=10) 2  6  6  2
  2 (n=5) 0  3  4  3
  3 (n=5) 2  1  1  3
N  0.642  0.285  0.213  0.114
  0 (n=24) 5  12  11  7
  1 (n=4) 1  1  0  2
  2 (n=2) 1  0  1  2
Stage  0.663  0.368  0.806  0.264
  IA (n=16) 3  9  7  6
  IB (n=8) 2  3  3  2
  IIA (n=2) 0  1  1  0
  IIB (n=2) 1  0  0  1
  IIIA (n=2) 1  0  1  2
Location  0.179  0.387  0.172  0.389
  Upper third (n=9) 1  5  3  3
  Middle third (n=15) 4  7  5  4
  Lower third (n=3) 0  0  3  2
  Remnant GC (n=3)  2  1  1  2
Age, years  0.089  0.462  0.590  0.421
  <65 (n=13) 1  5  5  4
  ≥65 (n=17) 6  8  7  7
Mean USS  0.623  0.515  0.073  0.310
  ≥2.2 (n=22)  5  9  11  7
  <2.2 (n=8) 2  4  1  4
AID, activation-induced cytidine deaminase; NF-κB, nuclear factor κB; PAX5, paired box 5; c-Myb, c-Myb proto-oncogene; T, tumor; ly, lymphatic; v, venous; 
N, node; GC, gastric carcinoma; USS, updated Sydney system. aStatistically significant.
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Figure 1. Representative histology, ISH and immunostaining images of EBV(+) GCLS, EBV(-) GC without LS and EBV(-) GCLS. H&E staining of (A) EBV(+) 
GCLS, (B) EBV(-) GC without LS and (C) EBV(-) GCLS. EBER1 ISH of (D) EBV(+) GCLS, (E) EBV(-) GC without LS and (F) EBV(-) GCLS. AID immu-
nostaining of (G) EBV(+) GCLS, (H) EBV(-) GC without LS and (I) EBV(-) GCLS. NF-κB immunostaining of (J) EBV(+) GCLS, (K) EBV(-) GC without LS 
and (L) EBV(-) GCLS. PAX5 immunostaining of (M) EBV(+) GCLS, (N) EBV(-) GC without LS and (O) EBV(-) GCLS. c-Myb immunostaining of (P) EBV(+) 
GCLS, (Q) EBV(‑) GC without LS and (R) EBV(‑) GCLS. Magnification, x100. (G, I) Red stars indicate AID expression as the positive internal control 
observed in the lymphoid cells of the germinal center. ISH, in situ hybridization; EBV, Epstein-Barr virus; GCLS, GC with LS; GC, gastric carcinoma; LS, 
lymphoid stroma; H&E, hematoxylin and eosin; EBER1, EBV-encoded small RNA 1; AID, activation-induced cytidine deaminase; NF-κB, nuclear factor κB; 
PAX5, paired box 5; c-Myb, c-Myb proto-oncogene.
Table III. Association between EBV infection and expression of AID and AID-regulatory factors in GC with or without LS.
   NF-κB (+)   PAX5 (+)   c-Myb (+)
 AID(+)   (AID activator)  (AID activator)  (AID silencer)
GC type (%) P-value (%) P-value (%) P-value (%) P-value
  0.025a  0.005a  0.01a  0.354
EBV(+) GC (n=11) 0 (0)  1 (9)  1 (9)  5 (45)
EBV(-) GC (n=19) 7 (37)  12 (63)  11 (58)  6 (32)
  NA  NA  NA  NA
EBV(+) LS(+) GC (n=10) 0 (0)  1 (10)  0 (0)  4 (40)
EBV(-) LS(+) GC (n=5) 3 (60)  0 (0)  2 (40)  3 (60)
  0.500  <0.001a  0.003a  0.256
LS(+) GC (n=15) 3 (20)  1 (7)  2 (13)  7 (47)
LS(-) GC (n=15) 4 (27)  12 (80)  10 (67)  4 (27)
EBV, Epstein-Barr virus; AID, activation-induced cytidine deaminase; GC, gastric carcinoma; LS, lymphoid stroma; NF-κB, nuclear factor κB; PAX5, paired 
box 5; c‑Myb, c‑Myb proto‑oncogene; NA, not applicable (insufficient case numbers for statistical analysis). aStatistically significant.
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increased compared with that of EBV-non-associated GCLS 
(66.9%) (P=0.009) (4). These results suggest that the EBV 
infection status in GC is an important prognostic factor. The 
aberrant expression of AID and AID-regulatory factors (NF-κB 
and c‑Myb) in the present study was not identified to be associ-
ated with clinicopathological parameters, whereas only PAX5 
expression was significantly associated with venous invasion. 
The relevance of AID and its regulatory factors for the survival 
rate of patients with GC was not demonstrated in the present 
study because only 1/30 patients succumbed to GC during the 
observation period.
In inflammation‑associated cancer development, in addition 
to infectious agents including H. pylori, a number of intrinsic 
mediators of inflammation, including proinflammatory cyto-
kines, growth factors, and reactive oxygen and nitrogen species, 
have the ability to induce the genetic and epigenetic modulation 
of tumor-related genes through various mechanisms, including 
enhancements in cell growth, mobility and angiogenesis, the 
inhibition of apoptosis and somatic gene mutations or rearrange-
ments, and DNA methylation (6,7). Furthermore, inflammation 
modulates the expression of microRNAs that influence the 
production of numerous tumor-related mRNAs or proteins (5). 
On the other hand, in the development of EBVaGC, mecha-
nisms other than the AID-induced genetic mutations described 
above, particularly DNA methylation, may have more important 
functions as the mechanisms underlying somatic gene muta-
tions through EBV-induced aberrant AID expression were not 
demonstrated in EBVaGC in the present study.
In the present study, significant aberrant expression of AID 
was not observed in EBVaGC and is considered irrelevant to the 
mechanisms underlying carcinogenesis in this specific subtype 
of GC, whereas aberrant AID expression contributes to carcino-
genesis in certain cases of EBV-non-associated GC.
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